Abstract library

420 results for "symptom improvement".
#849 Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide
Introduction: Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr. Matthew H Kulke
#451 Symptomatic Control of Neuroendocrine Tumors with Everolimus
Introduction: Everolimus prolongs progression-free survival, but previous research has not demonstrated its effect on symptoms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Hannah Bainbridge
Authors: Bainbridge H, Larbi E, Middleton G, ...
#133 Effectiveness of transarterial embolization of liver neuroendocrine metastases
Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dalvinder S Mandair
#2097 Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr. Barbara Kiesewetter
Authors: Kiesewetter B, Duan H, Haug A, Riss P, ...
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#2062 Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa
Introduction: LANRELO7484 is an ongoing, observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) in South Africa (SA).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Monique Nel
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life
#1387 FOLFOX in Neuroendocrine Tumors
Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Marjorie Faure
Authors: Faure M, Raoul J L, Autret A, Mineur L, ...